Drug intelligence / Profile preview

Bifidobacterium animalis subsp. lactis BAMA-B06

Development stage: Unknown
Lead developer: The Second Affiliated Hospital of Nanchang University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium animalis subsp. lactis BAMA-B06 is a specific probiotic strain being investigated for its therapeutic potential in managing functional constipation, particularly in patients with Parkinson's disease. As a live biotherapeutic product, it is intended to modulate the gut microbiota, improve intestinal barrier function, and enhance gastrointestinal motility. In clinical research conducted by the Second Affiliated Hospital of Nanchang University, BAMA-B06 is evaluated both as a monotherapy and in combination with traditional Chinese medicines like the Liuweianxiao capsule to address the non-motor symptoms of Parkinson's disease.

Other names: Bifidobacterium animalis subsp. lactis BAMA-B06

Beyond the preview

Go deeper on Bifidobacterium animalis subsp. lactis BAMA-B06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium animalis subsp. lactis BAMA-B06.

Explore the full profile